TY - JOUR
T1 - In depth characterization of physicochemical critical quality attributes of a clinical drug-dendrimer conjugate
AU - Sonzini, S
AU - Caputo, F
AU - Mehn, D
AU - Calzolai, L
AU - Borgos, SE
AU - Hyldbakk, A
AU - Treacher, K. E.
AU - Li, WM
AU - Jackman, M
AU - Mahmoudi, Najet
AU - Lawrence, MJ
AU - Patterson, C
AU - Owen, D
AU - Ashford, M
AU - Akhtar, N
PY - 2023/4/25
Y1 - 2023/4/25
N2 - A deep and detailed understanding of drug-dendrimer conjugates key properties is needed to define the critical quality attributes that affect drug product performance. The characterization must be executed both in the formulation media and in biological matrices. This, nevertheless, is challenging on account of a very limited number of suitable, established methods for characterizing the physicochemical properties, stability, and interaction with biological environment of complex drug-dendrimer conjugates. In order to fully characterize AZD0466, a drug-dendrimer conjugate currently under clinical development by AstraZeneca, a collaboration was initiated with the European Nanomedicine Characterisation Laboratory to deploy a state-of-the-art multi-step approach to measure physicochemical properties. An incremental complexity characterization approach was applied to two batches of AZD0466 and the corresponding dendrimer not carrying any drug, SPL-8984. Thus, the aim of this work is to guide in depth characterization efforts in the analysis of drug-dendrimer conjugates. Additionally, it serves to highlight the importance of using the adequate complementary techniques to measure physical and chemical stability in both simple and biological media, to drive a complex drug-dendrimer conjugate product from discovery to clinical development.
AB - A deep and detailed understanding of drug-dendrimer conjugates key properties is needed to define the critical quality attributes that affect drug product performance. The characterization must be executed both in the formulation media and in biological matrices. This, nevertheless, is challenging on account of a very limited number of suitable, established methods for characterizing the physicochemical properties, stability, and interaction with biological environment of complex drug-dendrimer conjugates. In order to fully characterize AZD0466, a drug-dendrimer conjugate currently under clinical development by AstraZeneca, a collaboration was initiated with the European Nanomedicine Characterisation Laboratory to deploy a state-of-the-art multi-step approach to measure physicochemical properties. An incremental complexity characterization approach was applied to two batches of AZD0466 and the corresponding dendrimer not carrying any drug, SPL-8984. Thus, the aim of this work is to guide in depth characterization efforts in the analysis of drug-dendrimer conjugates. Additionally, it serves to highlight the importance of using the adequate complementary techniques to measure physical and chemical stability in both simple and biological media, to drive a complex drug-dendrimer conjugate product from discovery to clinical development.
KW - Drug delivery
KW - Drug-dendrimer conjugate
KW - Nanomedicine
KW - Nanoparticle
KW - Physicochemical properties
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000982205000001&DestLinkType=FullRecord&DestApp=WOS
UR - http://www.scopus.com/inward/record.url?scp=85151846732&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/fcbb20aa-ac53-322f-aafb-7efe13165dc3/
U2 - 10.1016/j.ijpharm.2023.122905
DO - 10.1016/j.ijpharm.2023.122905
M3 - Article
C2 - 37003312
SN - 0378-5173
VL - 637
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 122905
ER -